|
|
 |
|
Viewing report
|
|
|
|
The Europe Biotechnology Sectors : A Company and Industry Analysis (October 2007)
Mergent, Oct 2007, Pages: 36
This report updates the previous European biotechnology report, focusing on the markets in France, Germany, the Netherlands, Sweden, Switzerland, and the United Kingdom
Current Environment - Key Points
- The past six months saw the maturing of European biotechs. A number of successful initial public offerings over the past six months suggested that biotechs are set to deliver products with potential for big returns. - US biotech indices, the NASDAQ Biotech index (+6.6%) and the AMEX Biotech index (+10.2%), outperformed the European WestLB Biotech index (+0.6%) between January 1 and May 15 this year. Leading biotechs recorded higher gains as the market capitalization of leading biotechs in Europe rose 5% between March 7 and September 21, according to a Mergent analysis. - Deal-making remained active in the past six months as drug giants snapped up promising therapies from smaller developers in order to beef up their pipelines. Qiagen (NASDAQ: QGEN) acquired US-based Digene for US$1.6 billion
- Seven European biotechs went public, raising a total of US$442 million, according to a Mergent analysis. The largest IPO was completed by Switzerland-s Addex Pharmaceuticals (SWX: ADXN) which raised CHF137 million (US$115.4 million) in May.
Industry Profile - Key Points
- A public-private partnership aimed at boosting new drug development in Europe, the Innovative Medicines Initiative (IMI), is on track to come into effect this year with total funding amounting to -2 billion (US$2.8 billion)
- Europe has taken a big step to aid SMEs, which presents another funding opportunity for biotech start-ups. The Eurostars Programme, under the EUREKA funding scheme, will be launched in October
- European Union (EU) ministers decided to forge ahead with a new EU system for centralized review of all gene, cell and tissue-based therapies in the EU by voting in favor of proposed regulations on advanced therapies. Europe will soon have a harmonized legal framework in place for these innovative products that could start as early as January 2008. - European biopharmaceutical companies now have to face extended preclinical testing requirements if their drug candidates fall into the newly created category of -high risk products-
Market Trends & Outlook - Key Points - Due to rising demand for biofuels, new processing routes for crude oil are being found. Over the next five years, the BIOCOUP project, supported through the Sixth Framework Programme for Research and Technical Development, will devise a series of steps that will allow biomass feedstock to be co-fed into a conventional oil refinery
- European researchers are developing techniques where artificially introduced RNAs are capable of canceling out disease causing proteins. The -11.8 million (US$16.4 million) Integrated Project will further investigate these methods with the aim of eventually making life threatening diseases a thing of the past. - Young researchers are looking to Europe to establish careers in stem cell research, due to initiatives such as the Marie-Curie mobility grants and the flagship project EuroStemCell, funded under the EU-s framework program
Customers who bought this item also bought
Cell Therapy - Technologies, Markets and Companies
Stem Cells Market And Applications, 2009-2015
Stem Cells Market And Technologies, 2009-2015
Stem Cells Market And Drug Discovery Applications, 2009-2015
Gene Therapy - Global Strategic Business Report
Human Embryonic Stem Cells (hESC) - A Global Market Overview
Stem Cells Research - Global Strategic Business Report
Gene Therapy - Technologies, Markets and Companies
Biorepositories: Applications & Ownership - A Global Market Watch, 2009-2015
Biobanking: End-Users - A Global Market Watch, 2009-2015
|
|
|
|
